恒瑞医药(600276.SH)获得阿得贝利单抗注射液等药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of multiple drug candidates, indicating a significant step forward in its research and development efforts [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries, including Suzhou Shengdiya Biopharmaceutical Co., Ltd., Shanghai Heng Rui Medicine Co., Ltd., and Shanghai Shengdi Medicine Co., Ltd., have been granted clinical trial approval for HRS-7058 capsules, HRS-7058 tablets, SHR-9839(sc), Adebali monoclonal antibody injection, Bevacizumab injection, and SHR-A2102 injection [1] - The approved clinical trials will focus on the safety, tolerability, and efficacy of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors, specifically a Phase II clinical study [1] Group 2: Regulatory Compliance - The approved drug candidates were reviewed and found to meet the requirements for drug registration as per the Drug Administration Law of the People's Republic of China [1] - The approval was based on the submission received on August 18, 2025, confirming compliance with relevant regulations [1]